Indication
Hemophilia A with inhibitor
7 clinical trials
7 products
Clinical trial
A Randomized, Open-label Study to Evaluate the Efficacy and Safety of KN057 Injection Prophylaxis in Patients With Hemophilia A or B With InhibitorsStatus: Recruiting, Estimated PCD: 2025-10-15
Product
KN057Clinical trial
An Open-label and Multicenter Phase Ib/II Clinical Trial to Evaluate the Safety, Immunogenicity, PK/PD Profile of SS109 and NovoSeven® Following a Single Dose, and the Preliminary Efficacy and Safety of SS109 During On-demand Treatment in Hemophilia Patients With Coagulation Factor VIII or IX InhibitorsStatus: Recruiting, Estimated PCD: 2024-05-31
Product
SS109Clinical trial
To Evaluate the Safety, PK/PD and Immunogenicity of SS109 in Hemophilia Patients With Blood Coagulation Factor Ⅷ or Ⅸ Inhibitors After Single Administration, Open Label, Dose Escalation, and Multicenter Phase I Clinical TrialStatus: Completed, Estimated PCD: 2023-03-31
Clinical trial
Safety of SEVENFACT® for the Treatment of Bleeding Events in Patients With Hemophilia A or B With InhibitorsStatus: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Phase 1/2 Safety, Tolerability, and Efficacy Study of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients With Active or Prior InhibitorsStatus: Recruiting, Estimated PCD: 2029-02-01
Product
Valoctocogene roxaparvovecClinical trial
The Outcome Comparison of Immune Tolerance Induction Therapy Using SCT800 Combined With Daratumumab or SCT800 Alone in Hemophilia A Adolescents and Adults With High Titer Inhibitor: a Non-randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2026-12-01
Product
SCT800Clinical trial
Phase III Multi-Center, Randomized, Controlled Inhibitor Eradication Trial, Comparing Eloctate Immune Tolerance Induction (ITI) Plus Emicizumab vs. Eloctate ITI Alone to Eradicate Inhibitor Formation in Severe Hemophilia AStatus: Terminated, Estimated PCD: 2022-06-27
Product
EloctateProduct
Emicizumab